Record mula sa primary source
Decision-gradeTopline na resulta
Xilio Therapeutics inaasahan ang Phase 1 data ng XTX501 sa 2H 2027
Nagbigay ang Xilio Therapeutics ng inaasahang timeline para sa unang Phase 1 data ng kanilang XTX501 program, isang bispecific PD-1 / masked IL-2 therapy. Inaasahan ng kumpanya na iulat ang data na ito sa ikalawang kalahati ng 2027, depende sa pag-clear ng FDA sa investigational new drug (IND) application, na nakatakda para sa kalagitnaan ng 2026.
Mahahalagang fact
- Na-file
- Mar 9, 2026, 12:00 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
XLOXilio Therapeutics- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 xlo-ex99_1.htm EX-99.1 Unlocking the Potential of Immuno-Oncology Therapies March 9, 2026 © 2026 Xilio Therapeutics, Inc. ® This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations related to: development timelines and anticipated milestones for Xilio’s programs; the ultimate safety, efficacy, and potential benefits of any of Xilio’s current or future product candidates in any indication; any potential indications or commercial opportunities of our product candidates; the timing and receipt of future payments under Xilio’s collaboration or partnership agreements with AbbVie and Gilead; Xilio’s preliminary, unaudi